Zimmer Biomet Holdings (ZBH) Tops Q2 EPS by 78c

Zimmer Biomet Holdings (NYSE: ZBH) reported Q2 EPS of $0.05, $0.78 better than the analyst estimate of ($0.73). Revenue for the quarter came in at $1.23 billion versus the consensus estimate of $909.41 million.

Financial Guidance

While Zimmer Biomet saw encouraging recovery in elective procedures during the second quarter, there continues to be uncertainty around the scope and duration of COVID-19 and its ongoing impact. Therefore, the Company is currently unable to quantify the expected impact on its results of operations, financial condition and cash flows, which could be material, for 2020 and is not providing full-year financial guidance at this time.

For earnings history and earnings-related data on Zimmer Biomet Holdings (ZBH) click here.

You May Also Be Interested In

• Zimmer Biomet to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
• Netskope, Inc. (NTSK) Tops Q1 EPS by 1c, Offers Guidance
• Morgan Stanley lifts MU and SNDK targets, sees 2-3 years of tight memory supply